30O Stock Overview
Engages in research and development of anti-body drugs; and the genome analysis of cancer, liquid biopsy, and development of new immunotherapy in Japan. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
OncoTherapy Science, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | JP¥0.15 |
| 52 Week High | JP¥0.36 |
| 52 Week Low | JP¥0.067 |
| Beta | 0.47 |
| 11 Month Change | 7.25% |
| 3 Month Change | -49.66% |
| 1 Year Change | 3.50% |
| 33 Year Change | -74.70% |
| 5 Year Change | -80.00% |
| Change since IPO | -95.77% |
Recent News & Updates
Recent updates
Shareholder Returns
| 30O | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 10.4% | -0.7% | -0.02% |
| 1Y | 3.5% | -17.2% | 8.2% |
Return vs Industry: 30O exceeded the German Biotechs industry which returned -17.5% over the past year.
Return vs Market: 30O underperformed the German Market which returned 7.4% over the past year.
Price Volatility
| 30O volatility | |
|---|---|
| 30O Average Weekly Movement | 20.8% |
| Biotechs Industry Average Movement | 6.4% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.9% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 30O's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 30O's weekly volatility (21%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2001 | 54 | Junichi Shimada | www.oncotherapy.co.jp |
OncoTherapy Science, Inc. engages in research and development of anti-body drugs; and the genome analysis of cancer, liquid biopsy, and development of new immunotherapy in Japan. Its development pipeline includes OTS167, a small molecular compound that targets the maternal embryonic leucine zipper kinase inhibitor that is in Phase I/II clinical trials for the treatment of acute myeloid leukemia, as well as in Phase I clinical trials for the treatment of breast cancer; and OTS964, a small molecule TOPK inhibitor currently under non-clinical stage. The company’s pipeline also comprises cancer peptide vaccines, including S-588410, which completed Phase III clinical trials for the treatment esophageal cancer, as well as Phase II clinical trials for the treatment of bladder cancer; S-488210, which is in Phase I/II clinical trials for the treatment of head and neck cancer; S-588210, which is in Phase I clinical trials for the treatment of solid tumor; and OTSGC-A24, currently in Phase I clinical trials for the treatment of gastric cancer.
OncoTherapy Science, Inc. Fundamentals Summary
| 30O fundamental statistics | |
|---|---|
| Market cap | €53.91m |
| Earnings (TTM) | -€6.96m |
| Revenue (TTM) | €2.97m |
18.1x
P/S Ratio-7.7x
P/E RatioIs 30O overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 30O income statement (TTM) | |
|---|---|
| Revenue | JP¥479.00m |
| Cost of Revenue | JP¥1.17b |
| Gross Profit | -JP¥687.00m |
| Other Expenses | JP¥436.00m |
| Earnings | -JP¥1.12b |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -4.13 |
| Gross Margin | -143.42% |
| Net Profit Margin | -234.45% |
| Debt/Equity Ratio | 0% |
How did 30O perform over the long term?
See historical performance and comparison